Therapeutic effects of arotinolol, a beta-adrenergic blocker, on tremor in MPTP-induced parkinsonian monkeys.

Abstract:

:The effect of arotinolol, a peripherally acting beta-adrenergic-blocking agent, on postural or kinetic tremor was studied in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Male cynomolgus monkeys (Macaca fascicularis) were treated with three injections of MPTP hydrochloride (0.3 mg/kg, i.v.) at an interval of 3-4 days, followed by several injections of the same dose every 7 days. Four monkeys with persistent parkinsonian symptoms manifested for greater than 1 year were used. The animals developed mild to moderate degrees of postural or kinetic tremor, and their motor activity was reduced. Arotinolol (20-30 mg/kg, s.c.) significantly suppressed postural tremor in a dose-dependent manner. Propranolol (20-30 mg/kg) was also effective in suppressing the tremor. However, the application of propranolol induced emesis, whereas arotinolol had no adverse effects. These results suggest that arotinolol is a useful adjunct to dopaminergic therapy for tremor in Parkinson's disease.

journal_name

Clin Neuropharmacol

authors

Kuno S,Mizuta E,Nishida J,Takechi M

doi

10.1097/00002826-199210000-00005

keywords:

subject

Has Abstract

pub_date

1992-10-01 00:00:00

pages

381-6

issue

5

eissn

0362-5664

issn

1537-162X

journal_volume

15

pub_type

杂志文章
  • A review of the randomized controlled trials of tacrine in the treatment of Alzheimer's disease: methodologic considerations.

    abstract::This review examines the features of the 16 randomized controlled trials that have been published on the use of oral tacrine for treating probable Alzheimer's disease and explores the methodologic problems associated with these studies. Patient selection using the standard National Institute of Neurological and Commun...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Conway EL

    更新日期:1998-01-01 00:00:00

  • Changes in Cognitive Processing Speed, Mood, and Fatigue in an Observational Study of Persons With Multiple Sclerosis Treated With Dalfampridine-ER.

    abstract:OBJECTIVE:Multiple sclerosis (MS) is a degenerative neurological condition that results in impairments in multiple domains including cognition, fatigue, and mood. Dalfampridine-extended release (D-ER) has been approved to improve walking in persons with MS. It is plausible that D-ER could improve cognition, fatigue, an...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000130

    authors: Triche EW,Ruiz JA,Olson KM,Lo AC

    更新日期:2016-03-01 00:00:00

  • One-Year Retention Study of Adjunctive Perampanel Treatment in Epilepsy Patients.

    abstract:OBJECTIVES:Perampanel is a recently introduced antiepileptic drug (AED) with a unique action mechanism of noncompetitive and selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist. Because of delayed approval of perampanel in most Asian countries, there is limited information on the clinical usefulne...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000255

    authors: Kim DW,Oh J

    更新日期:2018-01-01 00:00:00

  • Levodopa efficacy and pathological basis of Parkinson syndrome.

    abstract::Levodopa is the most effective drug for symptomatic control of Parkinson syndrome (PS). We report a 22-year clinicopathological study of 59 PS cases. Of the entire group, 37 (63%) had an adequate trial on levodopa. Some improvement was noted on that drug in 24 (65%) cases. Improvement was seen in 94% of idiopathic Par...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199012000-00007

    authors: Rajput AH,Rozdilsky B,Rajput A,Ang L

    更新日期:1990-12-01 00:00:00

  • Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments.

    abstract:OBJECTIVES:To describe further the phenomenology of drug-induced psychosis (DIP) in patients with Parkinson disease (PD) and assess which items on two common psychosis rating instruments-the Brief Psychiatric Rating Scale (BPRS) and the Neuropsychiatric Inventory (NPI)-are the best measure of DIP by comparing them with...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/01.wnf.0000180228.77802.32

    authors: Chou KL,Messing S,Oakes D,Feldman PD,Breier A,Friedman JH

    更新日期:2005-09-01 00:00:00

  • Paroxysmal dystonia responsive to anticholinergic drugs.

    abstract::A case of a mentally retarded patient with sporadic paroxysmal dystonia, unresponsive to anticonvulsant therapy, is described. He had a long-standing history of neuroleptic drug intake. Trihexyphenidyl in a total daily dosage of 20 mg totally suppressed the crises. ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198708000-00007

    authors: Micheli F,Fernandez Pardal M,de Arbelaiz R,Lehkuniec E,Giannaula R

    更新日期:1987-08-01 00:00:00

  • Side effects during long-term treatment with depot antipsychotic medication.

    abstract::During long-term treatment of schizophrenia with antipsychotic medication, side effects such as weight gain and tardive dyskinesia may develop, while other extrapyramidal side effects may continue. A large multicenter, double-blind, comparative trial of haloperidol decanoate and fluphenazine decanoate has been complet...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Cookson JC

    更新日期:1991-01-01 00:00:00

  • Knee Buckling (Negative Myoclonus) Associated With Clozapine: Reports on 3 Cases.

    abstract:BACKGROUND:Negative myoclonus is rarely seen in the clinical setting. It can be involved in some central nervous system pathologies. It has also been observed after antipsychotic treatment. CASE REPORTS:In this article, we will present 3 cases diagnosed with negative myoclonus in a 120-bed university-affiliated hospit...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000370

    authors: Uzun Ö,Bolu A,Taşçi AB,Oğur B

    更新日期:2020-01-01 00:00:00

  • Palinopsia induced by topiramate and zonisamide in a patient with migraine.

    abstract::Palinopsia is an illusory visual phenomenon consisting in the persistence or recurrence of visual images after the exciting stimulus object has been removed. It has been reported in association with parietal and occipital lobe lesions, migraine auras, and related to the use of several drugs and illicit drugs. Here, we...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/WNF.0b013e3182849208

    authors: Sierra-Hidalgo F,de Pablo-Fernández E

    更新日期:2013-03-01 00:00:00

  • Neuroleptic malignant syndrome from aripiprazole in an agitated pediatric patient.

    abstract:OBJECTIVE:Neuroleptic malignant syndrome was induced by aripiprazole in a 12 1/2-year-old boy. The patient had a history of reactive airway disease, pervasive developmental disorder, and learning disability. METHOD:The patient was interviewed and examined, and additional history was taken from the medical records. The...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/01.WNF.0000240941.13876.5E

    authors: Palakurthi HB,Parvin MM,Kaplan S

    更新日期:2007-01-01 00:00:00

  • Low-dose bromocriptine in the early phases of Parkinson's disease.

    abstract::The effect of bromocriptine at doses up to 20 mg/day was studied in a single-blind format with a placebo phase in 15 Parkinson's disease patients with mild-to-moderate disability who had not been previously treated with levodopa. For the 11 patients who completed the 9 month trial, both Northwestern University Disabil...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Tolosa E,Blesa R,Bayes A,Forcadell F

    更新日期:1987-04-01 00:00:00

  • Acute dystonic reaction in normal humans caused by catecholamine depletion.

    abstract::Five of 24 (21%) normal men (volunteers) administered alpha-methyl-para-tyrosine (AMPT), a catecholamine-depleting agent, developed acute dystonic reactions. The finding that catecholamine depletion without receptor blockade is sufficient to cause acute dystonia suggests that a variety of neurotransmitter imbalances m...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199012000-00009

    authors: McCann UD,Penetar DM,Belenky G

    更新日期:1990-12-01 00:00:00

  • Brain monoamine output alterations after a single venlafaxine challenge in experimental hepatic encephalopathy.

    abstract::Venlafaxine (VEN) pharmacokinetics and effects on the brain monoamine output were investigated in the context of experimental hepatic encephalopathy (HE). Systemic VEN (10 mg/kg; subcutaneous) was administered to chronic portacaval shunted (PCS) and sham-operated rats. Their neocortical extracellular levels of 5-HT, 5...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Wikell C,Bergqvist PB,Hjorth S,Apelqvist G,Björk H,Bengtsson F

    更新日期:1998-09-01 00:00:00

  • The effects of flumazenil in neuropsychiatric disorders.

    abstract::Flumazenil is a benzodiazepine receptor antagonist. It is currently used mainly in the anaesthetic and emergency rooms to reverse the effect of exogenous benzodiazepines. Its use in a variety of experimental animal models and in human neuropsychiatric disorders continues to generate a wealth of information on the poss...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199506000-00002

    authors: Malizia AL,Nutt DJ

    更新日期:1995-06-01 00:00:00

  • Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.

    abstract::Monoamine oxidase type B (MAO-B) is the predominant isoform responsible for the metabolic breakdown of dopamine in the brain. Selective inhibition of brain MAO-B results in elevation of synaptosomal dopamine concentrations. Data have been reported regarding the selective MAO-B inhibitors, rasagiline and selegiline, fo...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/01.wnf.0000240956.49315.be

    authors: Fernandez HH,Chen JJ

    更新日期:2007-05-01 00:00:00

  • Kleptomania after head trauma: two case reports and combination treatment strategies.

    abstract::The purpose of this paper is to add to the growing number of reports about kleptomania occurring in relation to brain injury as well as to present the authors' findings regarding treatment strategies. The authors present two case reports of patients who developed the new onset of kleptomania after closed head trauma. ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/01.wnf.0000144042.66342.d3

    authors: Aizer A,Lowengrub K,Dannon PN

    更新日期:2004-09-01 00:00:00

  • Lack of relation between genetic polymorphism of cytochrome P-450IID6 and sporadic idiopathic Parkinson's disease.

    abstract::We investigated genetic polymorphism of the cytochrome P-450 CYP2D6 gene from white patients with idiopathic Parkinson's disease (IPD). The mutations of the CYP2D6 gene associated with the poor metabolizer (PM) phenotype of the debrisoquine/sparteine polymorphism were analyzed in DNA of 130 IPD patients by a polymeras...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199619030-00003

    authors: Bordet R,Broly F,Destée A,Libersa C,Lafitte JJ

    更新日期:1996-06-01 00:00:00

  • Combined quinacrine and chlorpromazine therapy in fatal familial insomnia.

    abstract::Prion diseases are invariably fatal. Recently, quinacrine and chlorpromazine have been suggested as immediate candidates for the treatment of Creutzfeldt-Jakob disease and other prion diseases. The objective of this paper was to report on 2 fatal familial insomnia patients whose overall condition worsened despite quin...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/01.wnf.0000134853.36429.0e

    authors: Benito-León J

    更新日期:2004-07-01 00:00:00

  • Effective treatment with clozapine and valproate for refractory schizophrenia-like psychosis after cerebellar hemorrhage.

    abstract:BACKGROUND:The cerebellum has traditionally been regarded as an organ of motor coordination. However, the importance of the cerebellum in psychiatric disorders, behavior, and cognition is increasingly being recognized. There is no consensus concerning treatment of schizophrenia-like psychosis after cerebellar pathology...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31821f4d91

    authors: Almeida J,Serrão EM,Almeida AT,Afonso JG

    更新日期:2011-05-01 00:00:00

  • Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.

    abstract::Male albino rats received a stereotaxic injection of 6-hydroxydopamine (6-OHDA) into the right substantia nigra. Animals demonstrating contralateral rotations 2 weeks postoperatively with apomorphine (0.5 mg/kg i.p.) were treated with L-Dopa (55 mg/kg i.p.), bromocriptine (2 mg/kg i.p.), or polyethylene glycol (vehicl...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Schneider MB,Murrin LC,Pfeiffer RF,Deupree JD

    更新日期:1984-01-01 00:00:00

  • No effect of chronic bromocriptine therapy on levodopa pharmacokinetics in patients with Parkinson's disease.

    abstract::We studied the effect of chronic bromocriptine cotherapy on levodopa kinetics in seven patients with Parkinson's disease who were receiving levodopa therapy. Plasma levodopa concentrations were measured after a standard oral levodopa fasting dose over a 5-hour period, on two different sessions, without and with bromoc...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199212000-00008

    authors: Contin M,Riva R,Martinelli P,Albani F,Baruzzi A

    更新日期:1992-12-01 00:00:00

  • United States experience and perspectives with trazodone.

    abstract::In the United States, trazodone has shown efficacy comparable with tricyclic antidepressants. Trazodone's side-effect profile, however, is vastly superior to the older drugs. In cases of overdose, trazodone alone has not caused a single death. For depressed patients, starting with 150 mg/day of trazodone, preferably a...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,评审

    doi:10.1097/00002826-198901001-00003

    authors: Fabre LF

    更新日期:1989-01-01 00:00:00

  • Clinical implications of sustained dopaminergic stimulation.

    abstract::Fluctuations in motor performance are the major problems in chronic management of Parkinson's disease. Most of these fluctuations reflect the decline of levodopa availability. As a consequence, levodopa dosage might be increased and the interdose interval progressively shortened. The postsynaptic dopamine receptors at...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Stocchi F,Patsalos PN,Berardelli A,Barbato L,Bonamartini A,Manfredi M,Ruggieri S

    更新日期:1994-01-01 00:00:00

  • Diagnosis and assessment of age-associated memory impairment.

    abstract::Age-associated memory impairment (AAMI) is a diagnostic term applied to healthy persons greater than 50 years of age who have experienced a gradual decline in memory that lies within the boundaries of normality. Although the behavioral deficits associated with AAMI are modest in comparison to those associated with dem...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199013003-00009

    authors: Crook TH,Larrabee GJ,Youngjohn JR

    更新日期:1990-01-01 00:00:00

  • The effect of ascorbic acid on the pharmacokinetics of levodopa in elderly patients with Parkinson disease.

    abstract::Levodopa (LD) is one of the most effective drugs for clinical symptoms in patients with Parkinson disease (PD). Most PD patients are advanced in age and may have trouble with LD absorption because aging influences drug absorption processes. Previous reports have indicated that ascorbic acid (AsA) can reduce LD dosage ...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.wnf.0000150865.21759.bc

    authors: Nagayama H,Hamamoto M,Ueda M,Nito C,Yamaguchi H,Katayama Y

    更新日期:2004-11-01 00:00:00

  • Cytokine production in anorexia nervosa.

    abstract::The capacity of peripheral blood mononuclear cells (PBMCs) of anorexia nervosa (AN) patients to produce interleukin-1 (IL-1), interleukin-2 (IL-2), and interleukin-3-like activity (IL-3-LA) was studied. A significantly lower (-49%, p < 0.005) capacity to synthesize IL-2 and an almost significantly impaired ability (-3...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199306000-00007

    authors: Bessler H,Karp L,Notti I,Apter A,Tyano S,Djaldetti M,Weizman R

    更新日期:1993-06-01 00:00:00

  • Relief of intractable posthypoxic myoclonus after administration of agomelatine.

    abstract::Chronic posthypoxic myoclonus is characterized by myoclonic jerks that are specifically triggered by action. It is a rare but devastating sequela of hypoxic encephalopathy. We report a 42-year-old female patient with treatment-resistant chronic posthypoxic myoclonus, which improved with administration of the drug agom...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e3182613e06

    authors: González de la Aleja J,Saiz-Díaz RA,De la Peña P

    更新日期:2012-09-01 00:00:00

  • Cyclosporine A neurotoxicity among bone marrow transplant recipients.

    abstract::Cyclosporine A (CsA) neurotoxicity is an iatrogenic disease with significant morbidity and occasional mortality. We retrospectively reviewed the cases of CsA neurotoxicity among bone marrow transplant recipients at our institution, and summarized the current literature on the subject. The neurologic presentation is va...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199903000-00001

    authors: Shah AK

    更新日期:1999-03-01 00:00:00

  • Rotigotine Transdermal Patch Does Not Make Parkinson Disease Patients Sleepy During Daytime.

    abstract:OBJECTIVES:To assess quantitatively the influence of rotigotine transdermal patch on daytime sleepiness, the most common adverse event by non-ergot dopamine agonists (DAs), in Parkinson disease (PD) patients. METHODS:An open-label study enrolled PD patients with unsatisfactory control of motor symptoms. Treatment with...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000110

    authors: Ohta K,Osada T

    更新日期:2015-11-01 00:00:00

  • Effects of age on paroxetine efficacy in patients with major depressive disorder who do not exhibit an early response to treatment.

    abstract:OBJECTIVES:We investigated the effects of age on the association between early and eventual responses to paroxetine treatment in patients with major depressive disorder (MDD). METHODS:Eighty-nine patients with MDD were administered paroxetine and completed the 6-week protocol. On the basis of our previous study, we de...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000058

    authors: Tomita T,Sato Y,Nakagami T,Tsuchimine S,Kaneda A,Kaneko S,Nakamura K,Yasui-Furukori N

    更新日期:2015-01-01 00:00:00